Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Therapeutics Inc (NQ: APLT )

6.210 -0.240 (-3.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 745,079
Open 6.490
Bid (Size) 6.210 (4)
Ask (Size) 6.220 (153)
Prev. Close 6.450
Today's Range 6.050 - 6.570
52wk Range 1.180 - 9.390
Shares Outstanding 114,846,271
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Applied Therapeutics Reports Second Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. With govorestat (AT-007) poised... 
Via Benzinga

Performance

YTD
+70.60%
+70.60%
1 Month
+15.43%
+15.43%
3 Month
+40.18%
+40.18%
6 Month
+120.21%
+120.21%
1 Year
+311.26%
+311.26%

More News

Read More
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Applied Therapeutics Added to Russell 3000® Index
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics: Q4 Earnings Insights
Via Benzinga
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Via Benzinga
APLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Applied Therapeutics Reports First Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
From Applied Therapeutics
Via GlobeNewswire
FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease
Via Benzinga
Exposures Product Safety
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder
Via Benzinga
Exposures Product Safety
Why Is Coupang (CPNG) Stock Up 4% Today?
Via InvestorPlace
Applied Therapeutics Inc. (NASDAQ: APLT) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Why Is Applied Therapeutics (APLT) Stock Up 59% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.